a public good project by the
Synthesis
Company
of California

© 2026

Liping H. Pettus | doi.page

0 works0 citations0 h-index

Liping H. Pettus

Amgen (United States)(US)Université Bourgogne Franche-Comté(FR)

Publications by Year

Research Areas

Cancer-related gene regulation, Cancer Mechanisms and Therapy, Asymmetric Synthesis and Catalysis, Melanoma and MAPK Pathways, Synthesis and biological activity

Most-Cited Works

→ Desymmetrization of Benzoic Acid in the Context of the Asymmetric Birch Reduction−Alkylation Protocol. Asymmetric Total Syntheses of (−)-Eburnamonine and (−)-Aspidospermidine(1997)100 cited
→ Novel Vanilloid Receptor-1 Antagonists: 2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate(2007)98 cited
→ Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease(2014)85 cited
→ Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008(2008)71 cited
→ Discovery of Highly Selective and Potent p38 Inhibitors Based on a Phthalazine Scaffold(2008)58 cited
→ AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers(2024)56 cited

→ Synthesis of (±)-Epoxysorbicillinol Using a Novel Cyclohexa-2,5-dienone with Synthetic Applications to Other Sorbicillin Derivatives(2001)55 cited

→ MCC/SNAr methodology. Part 2: Novel three-step solution phase access to libraries of benzodiazepines(2003)53 cited

→ Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511(2012)50 cited

→ Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases(2012)49 cited